The majority of patients living with obesity do not have those complications
[DOI] [PMC free article] [PubMed] [Google Scholar] 57.Vargas F, Rodrguez-Gmez I, Vargas-Tendero P, Jimenez E, Montiel M
8.8%) These results are published in The New England Journal of Medicine (Wharton et al., 2025) and represent the strongest weight loss data ever seen from an oral GLP-1 candidate in Phase 3 trials
Strengthens global supply chains, benefiting patients worldwide
Brand-Name Drug Prices Fell for the Seventh Consecutive Year as a New Era of Drug Pricing Dawns.) They can also affect a patients out-of-pocket costs and access to a particular therapy
Injectable tirzepatide achieves 20-22% weight loss, while even optimized oral candidates typically achieve 8-12% weight loss in similar timeframes